loading page

Therapeutic Drug Monitoring in India : A SWOT analysis
  • +1
  • Smita Pattanaik,
  • Vikram Gota,
  • Santanu Tripathi,
  • Nilima Kshirsagar
Smita Pattanaik

Corresponding Author:[email protected]

Author Profile
Vikram Gota
Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer
Author Profile
Santanu Tripathi
Calcutta School of Tropical Medicine, Kolkata (formerly), N S Medical College and Hospital Patna, Bihar,
Author Profile
Nilima Kshirsagar
Indian Council of Medical Research
Author Profile


Over the last three to four decades, Therapeutic Drug Monitoring (TDM) has shaped itself as therapeutic drug management (TDM), an integral component of precision medicine. The practice of TDM is not extensive in India, despite being one of the fastest growing economies in the world. It is currently limited to a few academic medical centers and teaching hospitals. Apart from the immunosuppressive drugs, several other therapeutic areas like anticancer, antifungals, antibiotics and antitubercular have demonstrated great potential to improve the patient outcomes in the Indian settings. Factors like higher prevalence of nutritional deficiencies, tropical diseases, widespread use of alternative medicines, unalike pharmacogenomics, and sparse population specific data available on therapeutic ranges of several drugs, makes in the population of this subcontinent unique regarding the relevance of TDM. Despite the impact of TDM in clinical science and it’s widespread application, TDM has failed to receive the attention it deserves in India. This review intends to bring out a strength-weakness-opportunity and threats (SWOT) analysis for TDM in India so that appropriate steps for fostering growth of TDM could be envisioned. The need of the hour is creation of a cooperative group including all the stake holders like TDM professionals, clinicians and the government and devising a National Action Plan to strengthen TDM. Nodal TDM centres should be established and pilot programs should be rolled out for identifying the thrust areas for TDM in the country, capacity building and creating awareness to integrate TDM into mainstream clinical medicine.
10 Dec 2022Submitted to British Journal of Clinical Pharmacology
28 Dec 2022Submission Checks Completed
28 Dec 2022Assigned to Editor
28 Dec 2022Review(s) Completed, Editorial Evaluation Pending
03 Jan 2023Reviewer(s) Assigned
16 Jan 2023Editorial Decision: Revise Major
24 Mar 20231st Revision Received
24 Mar 2023Submission Checks Completed
24 Mar 2023Assigned to Editor
24 Mar 2023Review(s) Completed, Editorial Evaluation Pending
14 Apr 2023Editorial Decision: Revise Minor
26 Apr 20232nd Revision Received
26 Apr 2023Submission Checks Completed
26 Apr 2023Assigned to Editor
26 Apr 2023Review(s) Completed, Editorial Evaluation Pending
09 May 2023Editorial Decision: Accept